



# Thermo Fisher Scientific™ Accula™ System promotional offer

**Offer available from November 1, 2022 – December 31, 2022**

**Buy five (5) test kits for the price of four (4) test kits**

**Buy any combination of four (4) Accula SARS-CoV-2 or Flu A/Flu B Tests to qualify for this offer**

**Part numbers available in offer:**

- **Accula SARS-CoV-2:** COV4100
- **Accula Flu A/Flu B:** FAB1100CW

The promotional test kit will be sent directly to your office from Thermo Fisher Scientific

**Redeem:**

Contact your Thermo Fisher Scientific Account Manager or Call us at **858-401-8282** or

Email us at [accula.promo@thermofisher.com](mailto:accula.promo@thermofisher.com)

**Please provide your invoice to verify your purchase along with the following information:**

**Name:** \_\_\_\_\_

**Job title:** \_\_\_\_\_

**Phone:** \_\_\_\_\_ **Email:** \_\_\_\_\_

**Address:** \_\_\_\_\_

**City:** \_\_\_\_\_ **State:** \_\_\_\_\_ **Zip code:** \_\_\_\_\_

**Please select promotional kit:**

**Accula SARS-CoV-2:** \_\_\_\_\_ **Accula Flu A/Flu B:** \_\_\_\_\_

**Terms and Conditions:**

This promotion is open only to customers in the USA (excluding Puerto Rico) who purchase at least four (4) Accula SARS-CoV-2 or Flu A/Flu B test kits in a single purchase order. Offer valid for qualifying orders received by Thermo Fisher Scientific no later than December 31, 2022, or until promotional supplies are depleted, whichever comes first. Accula SARS-CoV-2 and Flu A/Flu B promotional kits are limited to three (3) redemptions per customer.

Cannot be combined with other discounts or promotions. Offer void where prohibited, licensed or restricted by federal, state, provincial, or local laws or regulation or agency/institutional policy. Other restrictions may apply.

Customer acknowledges that this offer may include a discount or other price reduction that must be properly and accurately accounted for and reported by customer in accordance with all federal and state laws, including without limitation the federal anti-kickback law (42 U.S.C. § 1320a-7b(b)(3)(A)) and regulations thereunder (42 C.F.R. §1001.952(h)).

The Accula SARS-CoV-2 Test has not been FDA cleared or approved but has been authorized for emergency use by FDA for use by laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. §263a, that meet requirements to perform high, moderate, or waived complexity tests. The test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.